Product Description
AbobotulinumtoxinA injection is used to relieve the symptoms of cervical dystonia (spasmodic torticollis; uncontrollable tightening of the neck muscles that may cause neck pain and abnormal head positions). It is also used to temporarily smooth frown lines (wrinkles between the eyebrows). AbobotulinumtoxinA injection is used to treat spasticity (muscle stiffness and tightness) of muscles in the arms and legs in adults and children 2 years of age and older. AbobotulinumtoxinA injection is in a class of medications called neurotoxins. It works by blocking the nerve signals that cause uncontrollable tightening and movement of the muscles. (Sourced from: https://medlineplus.gov/druginfo/meds/a609035.html)
Mechanisms of Action: SNAP-25 Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Chile | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Ireland | Italy | Latvia | Malaysia | Mexico | Morocco | New Zealand | Norway | Philippines | Russia | South Africa | Spain | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ipsen
Company Location:
Company CEO: David Loew
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Czech Republic, France, Germany, Iran, Italy, Poland, Spain, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Depressive Disorder, Major|Glabellar Reflex|Headache Disorders|Migraine Disorders|Musculoskeletal Pain|Pain, Postoperative
Phase 2: Carpal Tunnel Syndrome|Neuropathic Pain
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2021-006048-29 |
BotulInum toxin type A for peripheral Neuropathic pain | P2 |
Completed |
Neuropathic Pain|Carpal Tunnel Syndrome |
2025-01-08 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2023-504839-40-00 |
CLIN-52120-464 | P3 |
Recruiting |
Migraine Disorders |
2025-12-31 |
51% |
2025-05-02 |
Treatments |
NCT06946160 |
BOT.ESP.AF.III.02 | P3 |
Completed |
Glabellar Reflex |
2025-02-18 |
2025-05-08 |
Primary Endpoints|Treatments |
|
NCT03887377 |
NCT03887377 | P3 |
Completed |
Musculoskeletal Pain|Headache Disorders|Depressive Disorder, Major|Pain, Postoperative |
2024-12-30 |
27% |
2025-06-17 |
Primary Endpoints|Treatments|Trial Status |
2023-504827-17-00 |
CLIN-52120-463 | P3 |
Recruiting |
Migraine Disorders |
2025-12-30 |
51% |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/14/2026 |
News Article |
New data reinforces Ipsen's commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS |
|
12/29/2025 |
News Article |
IvesMD Opens New Beverly Hills Headquarters, Expands Team to Meet Growing Demand for Inclusive Aesthetic and Gender-Affirming Care |
|
12/11/2025 |
News Article |
Guidepoint Qsight Releases Report on $6Bn+ US Neurotoxin Use State-by-State |
|
10/29/2025 |
News Article |
The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year |